查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1451722

2024-2032 年按藥物類型、治療領域、最終用戶和地區分類的免疫療法藥物市場報告

Immunotherapy Drugs Market Report by Drug Type, Therapy Area, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2023年全球免疫療法藥物市場規模達2,130億美元。展望未來， IMARC Group預計到2032年市場規模將達到4,255億美元，2024-2032年複合年成長率（CAGR）為7.75%。由於人口老化，不同癌症類型的盛行率不斷上升，對個人化藥物的需求不斷成長，以及個人對早期檢測和治療的意識不斷增強，是推動市場的一些主要因素。

免疫治療藥物是一種旨在利用或改變免疫系統來對抗或控制疾病的醫學治療方法。它們專注於特定的細胞和蛋白質，有助於最大限度地減少對健康組織的傷害。與其他治療方法相比，它們可以降低產生抗藥性的可能性，提供更好的結果，並且副作用更少。它們用於治療各種類型的癌症，包括黑色素瘤、肺癌和乳腺癌。它們也用於控制特定的過敏反應和治療類風濕性關節炎、狼瘡和多發性硬化症等疾病。除此之外，由於它們能有效控制慢性發炎性疾病，全球對免疫療法藥物的需求正在增加。

製藥業的崛起和全球藥局的擴張提供了良好的市場前景。此外，生物技術公司、製藥公司和研究機構之間的策略合作和併購（M＆A）正在支持免疫療法產品的研究、開發和商業化活動。此外，人工智慧（AI）和巨量資料分析在研發（R＆D）活動中的整合正在提高效率和精確度。這種技術整合能夠快速識別目標、最佳化臨床試驗以及預測患者反應。

免疫治療藥物市場趨勢/促進因素：

目標疾病盛行率不斷上升

由於生活方式的改變和不健康的飲食模式，不同類型癌症的發生率不斷上升，這促使對免疫療法等創新和有效治療方法的需求不斷成長。此外，早期檢測和對個人化治療方案的需求正在鼓勵患者和醫療保健提供者採用這些先進的治療方案。除此之外，快速的城市化和有害車輛排放造成的污染水平上升正在導致各種慢性疾病，這為免疫療法創造了新的機會。此外，人口老化日益嚴重，極易患腫瘤、癌症和其他健康狀況，這推動了對有效治療和技術（如免疫療法藥物）的需求。

採用個人化藥物

個人化藥物在各個醫療領域的使用越來越多，以促進更以患者為中心的方法，這對市場產生了積極影響。此外，先進診斷工具（例如下一代定序和生物標記分析）的開發使得能夠精確識別患者以進行特定免疫療法。這些診斷學的進步促進了早期干預並允許個性化治療計劃，這有助於提高免疫療法的整體有效性。除此之外，個人化免疫療法也減少了試誤方法的可能性。此外，這種有針對性的方法可以最大限度地減少無效治療的使用，避免不必要的副作用，促進更快的康復，並降低醫療成本，這有助於市場成長。

政府和監管支持

各國政府和監管機構持續關注免疫療法藥物和療法的開發，市場前景良好。此外，他們也為開發新型免疫療法和最佳化現有免疫療法所需的深入研究提供財政支持。除此之外，政府、研究機構和私人公司之間的合作正在支持市場成長。這些合作促進了知識交流並加速了突破性跨境免疫療法的發展。此外，多項支持性政府醫療保健政策的推出正在鼓勵免疫療法的採用和報銷。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球免疫治療藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類型

  • 單株抗體
    • 市場走向
    • 市場預測
  • 疫苗
    • 市場走向
    • 市場預測
  • 干擾素α和BETA
    • 市場走向
    • 市場預測
  • 白血球介素
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依治療領域

  • 癌症
    • 市場走向
    • 市場預測
  • 自體免疫疾病與發炎性疾病
    • 市場走向
    • 市場預測
  • 傳染性疾病
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 診所
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112024A6639

The global immunotherapy drugs market size reached US$ 213.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 425.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.75% during 2024-2032. The growing prevalence of different cancer types due to the aging population, rising demand for personalized medicines, and the increasing awareness among individuals about early detection and treatment are some of the major factors propelling the market.

Immunotherapy drugs are medical treatments designed to utilize or modify the immune system to fight or control diseases. They focus on specific cells and proteins and aid in minimizing harm to healthy tissues. They reduce the likelihood of developing resistance, offer better outcomes, and have fewer side effects as compared to other treatments. They are utilized in treating various types of cancers, including melanoma, lung, and breast cancer. They are also used in managing specific allergic reactions and treating diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Besides this, as they are effective in controlling chronic inflammatory diseases, the demand for immunotherapy drugs is increasing across the globe.

The rise in the pharmaceutical industry and the expansion of pharmacies worldwide is offering a favorable market outlook. Moreover, strategic collaborations and mergers and acquisitions (M&A) between biotech firms, pharmaceutical companies, and research institutions are supporting the research, development, and commercialization activities of immunotherapy products. Furthermore, the integration of artificial intelligence (AI) and big data analytics in research and development (R&D) activities is enhancing efficiency and precision. This technological integration is enabling the rapid identification of targets, optimization of clinical trials, and prediction of patient responses.

Immunotherapy Drugs Market Trends/Drivers:

The increasing prevalence of target diseases

The rising occurrence of different types of cancer due to lifestyle changes and unhealthy dietary patterns is catalyzing the demand for innovative and effective treatments like immunotherapy is growing. Additionally, the early detection and need for personalized therapy options are encouraging patients and healthcare providers to adopt these advanced treatment alternatives. Apart from this, rapid urbanization and rising pollution levels due to harmful vehicular emissions are resulting in various chronic diseases, which is creating new opportunities for immunotherapy treatments. Furthermore, the increasing aging population, which is highly susceptible to tumor, cancer, and other health conditions, is driving the need for effective treatments and technologies, like immunotherapy drugs.

Adoption of personalized medicines

The increasing utilization of personalized medicines in various medical fields to promote a more patient-centered approach is positively influencing the market. Additionally, the development of advanced diagnostic tools, such as next-generation sequencing and biomarker analysis, is enabling the precise identification of patients for specific immunotherapies. These advancements in diagnostics facilitate early intervention and allow for personalized treatment plans, which aid in enhancing the overall effectiveness of immunotherapy. Apart from this, personalized immunotherapies reduce the likelihood of trial-and-error approaches. Furthermore, this targeted approach minimizes the use of ineffective treatments, avoids unnecessary side effects, facilitates quicker recoveries, and reduces healthcare costs, which is contributing to market growth.

Governmental and regulatory support

Governments and regulatory bodies of various countries are continuously focusing on the development of immunotherapy drugs and therapies, which is offering a favorable market outlook. Additionally, they are providing financial support for conducting the in-depth studies required to develop novel immunotherapies and optimize existing ones. Apart from this, partnerships between governments, research institutions, and private companies are supporting market growth. These collaborations facilitate knowledge exchange and accelerate the development of groundbreaking immunotherapy treatments across borders. Furthermore, the introduction of several supportive governmental healthcare policies is encouraging the adoption and reimbursement of immunotherapies.

Immunotherapy Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global immunotherapy drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type, therapy area and end user.

Breakup by Drug Type:

Monoclonal Antibodies

Vaccines

Interferons Alpha and Beta

Interleukins

Monoclonal antibodies represent the largest market segment

A detailed breakup and analysis of the market based on the drug type has also been provided in the report. This includes monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins. According to the report, monoclonal antibodies accounted for the largest market share. These antibodies offer a highly specific and targeted approach. They are designed to attach distinct proteins and receptors on the surface of diseased cells, enabling precise intervention. Additionally, regulatory bodies support monoclonal antibody therapies, providing streamlined approval processes and encouraging rapid development and commercialization. Apart from this, ongoing research and investment into the development of monoclonal antibodies contribute to their dominant position in the market. Furthermore, increasing funding and collaboration within the scientific community continue to yield innovative solutions. Moreover, technological advancements in manufacturing processes are making the production of monoclonal antibodies more scalable and cost-effective.

Breakup by Therapy Area:

Cancer

Autoimmune and Inflammatory Diseases

Infectious Diseases

Others

Cancer accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the therapy area. This includes cancer, autoimmune and inflammatory diseases, infectious diseases, and others. According to the report, cancer represented the largest segment. The rising prevalence of cancer due to the aging population, lifestyle changes, and environmental factors represent one of the key factors positively influencing the market. Additionally, the growing awareness among individuals about the benefits of early diagnosis and treatment of cancer is catalyzing the demand for immunotherapy drugs. Immunotherapy offers targeted treatments that can identify and attack specific cancer cells, minimizing damage to healthy tissue, enhancing effectiveness, and reducing side effects. Apart from this, continuous investments from governmental bodies, private sectors, and philanthropic organizations are supporting cancer research, including the development of immunotherapies, which is offering a favorable market outlook. Furthermore, rising partnerships between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development and accessibility of cancer immunotherapies.

Breakup by End User:

Hospitals

Clinics

Others

Hospitals hold the majority of the market share

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals hold the largest market share. Hospitals have a multidisciplinary team of specialists, including oncologists, immunologists, pharmacists, and nurses. These integrated teams enable a collaborative approach to patient care, ensuring the appropriate application and monitoring of immunotherapies. Additionally, they are equipped with state-of-the-art medical technologies and equipment. This access allows for the utilization of advanced immunotherapies. Apart from this, collaborations with pharmaceutical companies allow hospitals to gain early access to new immunotherapy drugs and technologies. These partnerships enhance the ability of hospitals to offer cutting-edge treatment options. Furthermore, they have established relationships with insurance providers and a better understanding of reimbursement policies. Moreover, many hospitals are involved in clinical trials and research collaborations, actively contributing to the advancement of immunotherapy.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest immunotherapy drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share as the region has a well-established healthcare infrastructure that allows for the efficient distribution and utilization of immunotherapy drugs. Sophisticated medical facilities and well-trained healthcare professionals facilitate the widespread adoption of these treatments. Additionally, the region witnesses substantial investments from public and private sectors in healthcare and biotechnology, which facilitates research, drug development, and commercialization of immunotherapy products. Apart from this, the regulatory bodies in North America, such as the Food and Drug Administration (FDA), offer a conducive environment for drug approval. Furthermore, strategic collaborations between academia, biotech firms, and pharmaceutical companies ensure a dynamic environment for continuous innovation and growth in the field of immunotherapy.

Competitive Landscape:

Companies are actively engaged in various activities to stay competitive and innovate. They are conducting extensive research and development (R&D) activities, working on discovering new targets and optimizing existing therapies. Additionally, these companies are forming strategic partnerships with academic institutions, leveraging their expertise to fuel innovation. Apart from this, they are investing in cutting-edge manufacturing technologies to produce immunotherapy drugs efficiently and at scale. Furthermore, regulatory teams within these companies are collaborating with governmental bodies to ensure compliance with emerging rules and gain expedited approvals for novel treatment. Moreover, many companies are actively participating in international conferences and symposia, sharing knowledge, and learning from global peers.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca plc

Bayer AG

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

F. Hoffmann-La Roche AG

GSK plc

Merck & Co. Inc.

Pfizer Inc.

Sanofi S.A.

Recent Developments:

In January 2022, Pfizer Inc. and BioNTech SE entered a strategic collaboration to develop an mRNA-based vaccine to prevent shingles.

In March 2023. Sanofi S.A. announced that it has received marketing authorization for Dupixent (dupilumab), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in children.

In January 2021, Enara Bio and Boehringer Ingelheim International GmbH announced a strategic collaboration and licensing agreement for the research and development (R&D) of novel targeted cancer immunotherapy.

Key Questions Answered in This Report

  • 1. How big is the global immunotherapy drugs market?
  • 2. What is the expected growth rate of the global immunotherapy drugs market during 2024-2032?
  • 3. What are the key factors driving the global immunotherapy drugs market?
  • 4. What has been the impact of COVID-19 on the global immunotherapy drugs market?
  • 5. What is the breakup of the global immunotherapy drugs market based on the drug type?
  • 6. What is the breakup of the global immunotherapy drugs market based on the therapy area?
  • 7. What is the breakup of the global immunotherapy drugs market based on the end user?
  • 8. What are the key regions in the global immunotherapy drugs market?
  • 9. Who are the key players/companies in the global immunotherapy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunotherapy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Interferons Alpha and Beta
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Interleukins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune and Inflammatory Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim International GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Immunotherapy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Immunotherapy Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Immunotherapy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Immunotherapy Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Immunotherapy Drugs Market: Breakup by Therapy Area (in %), 2023
  • Figure 6: Global: Immunotherapy Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Immunotherapy Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Immunotherapy Drugs (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Immunotherapy Drugs (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Immunotherapy Drugs (Interleukins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Immunotherapy Drugs (Interleukins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Immunotherapy Drugs (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Immunotherapy Drugs (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Immunotherapy Drugs (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Immunotherapy Drugs (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Immunotherapy Drugs (Other Therapy Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Immunotherapy Drugs (Other Therapy Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Immunotherapy Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Immunotherapy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Immunotherapy Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Immunotherapy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Immunotherapy Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Immunotherapy Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Immunotherapy Drugs Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Immunotherapy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Immunotherapy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Immunotherapy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunotherapy Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Immunotherapy Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Immunotherapy Drugs Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
  • Table 4: Global: Immunotherapy Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Immunotherapy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Immunotherapy Drugs Market: Competitive Structure
  • Table 7: Global: Immunotherapy Drugs Market: Key Players